Skip to main content
Get facts, not fiction
Published • loading... • Updated

One year after MFN: How US policy is reshaping the global pharma model

Summary by Pharmaphorum
Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

2 Articles

New drugs that can be used overseas are not available in Japan—such a future is becoming a reality. We will approach the impact of America's drug price policy “most-favoured-nation treatment (MFN)” on the Japanese market and the structural issues behind the global drug discovery competition behind drug price revisions.

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Pharmaphorum broke the news on Monday, October 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal